• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Cytek Biosciences Inc.

    5/30/25 4:00:54 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email
    SD 1 d919741dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    Cytek Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40632   47-2547526

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    47215 Lakeview Boulevard

    Fremont, California 94538

    (Address of principal executive offices)(Zip code)

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    (877) 922-9835

    (Name and telephone number, including area code, of the person to contact in connection with this report)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2024 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended __________.

     

     
     


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    This Specialized Disclosure Report on Form SD (the “Form SD”) of Cytek Biosciences, Inc. (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024. The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified in the Rule are necessary to the functionality or production of those products. The minerals specified in the rule are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin, tungsten and gold (collectively, the “3TG Minerals”). These requirements apply to registrants whether or not the 3TG Minerals in their supply chain originated in the Democratic Republic of the Congo or an adjoining country (Angola, Burundi, The Central African Republic, The Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda and Zambia) (together, the “Covered Countries”). As provided by applicable guidance from the U.S. Securities and Exchange Commission (the “SEC”) regarding the Rule, this disclosure does not address products that did not enter the stream of commerce in the calendar year ending December 31, 2024.

    The following disclosure, in response to the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD, has been made in accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporation Finance of the SEC on April 7, 2017 (the “April 2017 Guidance”). As permitted under the April 2017 Guidance, this Form SD does not address Item 1.01(c) of Form SD.

    Conflict Minerals Disclosure

    Overview

    The Company is a leading cell analysis solutions company advancing the next generation of cell analysis tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The Company’s products include flow cytometry instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.

    This Form SD relates to products of the Company (i) for which 3TG Minerals are necessary to the functionality or production of that product; (ii) that were manufactured, or contracted to be manufactured, by the Company; and (iii) for which the manufacture was completed during 2024. These products consist of the Company’s flow cytometry instruments, including the Cytek Aurora, Northern Lights, Northern Lights CLC, Aurora CS, DxP Athena and Amnis- and Guava-branded systems for cell analysis, the Cytek Orion system for reagent cocktail preparation and sample loading systems, and related parts and accessories (collectively, the “Covered Products”).

    The Company’s manufacturing operations are located in Fremont, California; San Diego, California; Seattle, Washington; Singapore; and Wuxi, China. The Fremont facility manufactures the Cytek Aurora and Aurora CS systems and spare parts; the San Diego facility manufactures reagents; the Seattle facility manufactures Amnis instruments and spare parts; the Singapore facility manufactures Cytek Aurora, Aurora CS and Northern Lights instruments; and the Wuxi facility manufactures the Cytek Aurora, Northern Lights, Guava and DxP Athena instruments, certain reagents and spare parts.

    The Company’s supply chain with respect to the Covered Products is complex, and there are many third parties in the supply chain between the original sources of 3TG Minerals and the ultimate manufacturing of the Covered Products. The Company does not purchase 3TG Minerals directly from mines, smelters or refiners and must, therefore, rely on its suppliers to provide information regarding the origin of the 3TG Minerals that are necessary to the functionality or production of the Covered Products. The Company expects its suppliers to maintain systems of control and transparency over its mineral supply chains. The Company is committed to conducting its business worldwide with respect for human rights and in compliance with applicable laws.

    Reasonable Country of Origin Inquiry

    The Company has, in good faith and after reasonable due diligence, conducted a reasonable country of origin inquiry (“RCOI”) to determine whether 3TG Minerals that are necessary to the functionality or production of its Covered Products originated in the Covered Countries, or whether any of the 3TG Minerals may have been from recycled or scrap sources.


    As an initial step, key personnel in the Company’s manufacturing, supply chain and purchasing functions were asked to evaluate the Company’s products to determine if 3TG Minerals may have been present and potentially necessary to the production or functionality of any product and to create a list of suppliers of components used in Covered Products during the reporting year ended December 31, 2024 (“Suppliers”).

    Thereafter, the Company directly contacted the Suppliers and conducted a supply-chain survey using the Conflict Minerals Reporting Template from the Responsible Minerals Initiative (“CMRT”). The CMRT is a standardized reporting template designed to facilitate the transfer of information through the supply chain regarding mineral country of origin and the smelters and refiners being utilized. Most Suppliers provided “company-level” CMRT responses for all products sold by such Supplier during the reporting year although the Company purchased only a limited subset of such products. The Company reviewed the CMRT responses for completeness, consistency, and accuracy, and, with respect to some matters, requested and received further written evidence to validate or clarify responses. For components that are not directly manufactured by the Suppliers, the Company relied on the Suppliers to conduct a RCOI to determine whether 3TG Minerals were contained in these components and relied on the CMRTs provided by the Suppliers from their suppliers or manufacturers.

    The Company believes its RCOI process was reasonably designed and performed in good faith. However, there are inherent limitations in the information provided by third parties, including but not limited to: gaps in Supplier and smelter data; errors or omissions by Suppliers or smelters; gaps in Supplier education and knowledge; timeliness of data; public information not discovered during a reasonable search; and Supplier and smelter unfamiliarity with the protocols for identifying and sourcing 3TG Minerals.

    Determination

    Based on this RCOI, the Company has reason to believe that certain 3TG Minerals contained in some Covered Products may have originated in a Covered Country and are not from recycled or scrap sources. Most Suppliers reported that 3TG Minerals either were not present, not sourced from Covered Countries, or were sourced primarily from smelters or refiners certified as “conflict free.” Three Suppliers have represented that their products contain 3TG Minerals originating from the Covered Countries; however, each of these Suppliers has further represented that such 3TG Minerals were sourced from smelters or refiners that are either conformant with, or otherwise in compliance with, the Responsible Mineral Assurance Process (“RMAP”) standards. Additionally, two other Suppliers have represented that their products contain 3TG Minerals from the Covered Countries; however, these Suppliers have represented that such minerals were sourced from smelters or refiners that have been approved as compliant with the applicable Conflict-Free Smelter Program (“CFSP”) Assessment Protocols. In addition, a small number of Suppliers acknowledged the presence of 3TG Minerals without being able to identify their source or the status of the smelters or refiners, with ongoing due diligence, or reported sourcing from identified smelters recognized and listed by the Responsible Minerals Initiative’s smelter database but without confirmation of their RMAP status. Some Suppliers failed to respond or provide complete responses notwithstanding multiple requests from the Company. Accordingly, the Company cannot reasonably determine whether 3TG Minerals were included in components from such Suppliers and/or the exact source of 3TG Minerals incorporated into such components, if at all.

    Additional Information

    A copy of this Form SD can be found on our corporate website at www.cytekbio.com. The Company’s website and the information accessible through the website are not incorporated by reference into this Form SD.

    Item 1.02 Exhibit

    None.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Cytek Biosciences, Inc.
    Date: May 30, 2025     By:   /s/ Wenbin Jiang
         

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    Get the next $CTKB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    8/17/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/3/25 5:39:17 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chin Richard

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:31:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Chin Richard

      3 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:27:18 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Neff Deborah J

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:25:14 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/22/24 7:07:27 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Financials

    Live finance-specific insights

    See more
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

      2/27/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek Announces Resignation of Chief Operating Officer Chris Williams

      FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

      9/12/24 3:20:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Names William McCombe Chief Financial Officer

      Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

      3/19/24 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

      1/31/25 6:59:30 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Stephens initiated coverage on Cytek Biosciences with a new price target

      Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

      12/14/23 6:55:41 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

      FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora E

      5/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

      FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next

      5/28/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    SEC Filings

    See more
    • SEC Form 8-K filed by Cytek Biosciences Inc.

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      6/24/25 4:05:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Cytek Biosciences Inc.

      SD - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/30/25 4:00:54 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

      SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      5/15/25 2:07:36 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials